{
    "id": 3396,
    "fullName": "KIT D820V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KIT D820V lies within the protein kinase domain of the Kit protein (UniProt.org). D820V has been identified as a secondary mutation associated with imatinib resistant (PMID: 18294292), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11778,
                    "pubMedId": 18294292,
                    "title": "Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18294292"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "D820V",
    "createDate": "02/26/2015",
    "updateDate": "09/22/2019",
    "referenceTranscriptCoordinates": {
        "id": 136108,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54733167A>T",
        "cDna": "c.2459A>T",
        "protein": "p.D820V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12313,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ayvakit (avapritinib) treatment resulted in tumor reduction lasting through 15 cycles of treatment in a patient with gastrointestinal stromal tumor harboring KIT D820V, whose disease had progressed on previous Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib) treatment (PMID: 29093181; NCT02508532).",
            "molecularProfile": {
                "id": 3206,
                "profileName": "KIT D820V"
            },
            "therapy": {
                "id": 2941,
                "therapyName": "Avapritinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10301,
                    "pubMedId": 29093181,
                    "title": "A precision therapy against cancers driven by KIT/PDGFRA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29093181"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14617,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KIT D816E and D820V were identified as secondary mutations in a patient with gastrointestinal stromal tumor harboring KIT W557_K558del who developed resistance to Gleevec (imatinib) (PMID: 18294292).",
            "molecularProfile": {
                "id": 31758,
                "profileName": "KIT W557_K558del KIT D816E KIT D820V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11778,
                    "pubMedId": 18294292,
                    "title": "Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18294292"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3206,
            "profileName": "KIT D820V",
            "profileTreatmentApproaches": [
                {
                    "id": 1473,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT D820V"
                }
            ]
        },
        {
            "id": 30368,
            "profileName": "KIT D816E KIT D820V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31758,
            "profileName": "KIT W557_K558del KIT D816E KIT D820V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136108,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54733167A>T",
            "cDna": "c.2459A>T",
            "protein": "p.D820V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136109,
            "transcript": "XM_005265741",
            "gDna": "chr4:g.54733167A>T",
            "cDna": "c.2459A>T",
            "protein": "p.D820V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}